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1. Introduction 
Gene therapy and treatment with siRNA hold potential to treat a wide variety of different 
diseases. Genetic material is not usually stable and is generally hydrolyzed following 
intravascular administration. This makes the delivery of genes somewhat problematic since 
intact genetic material must usually be delivered intracellularly for therapeutic effect. For 
gene therapy, in most cases the gene construct must reach the cellular intranuclear sub-
compartment in order to elicit the desired biological effect. Viruses have evolved to deliver 
DNA and RNA to cells but viral vector-based gene therapy has been associated with effects 
inherent in biological systems (Marshall, Muruve, Thomas). Non-viral based systems afford 
the potential to deliver genetic materials without the adverse biological effects of viral-based 
systems. In most cases, however, non-viral based gene delivery systems have been less 
effective than viral based systems, yielding lower levels of gene expression (Litzinger). 
Microbubbles, e.g. acoustically active carriers, in concert with ultrasound (Unger, Zhou) 
may afford potential for highly effective site directed gene therapy and delivery of other 
genetic materials such as siRNA (Zhigang). 
2. Summary of gene delivery with microbubbles and ultrasound 
The basic outline of a microbubble is shown in Figure 1.  Microbubbles are composed of gas 
with a stabilizing shell material oftentimes consisting of lipids, albumin, or biocompatible 
polymers. For biomedical application they range in size from several microns in diameter to 
several hundred nanometers in diameter. The original biomedical application was as 
ultrasound contrast agents for echocardiography. Two agents, Definity®, phospholipid-
coated perfluoropropane microbubbles (Lantheus, Billerica, MA) and Optison®, albumin-
coated perfluoropropane microbubbles, are approved by the FDA in the US and are sold as 
contrast agents with approved claims for echocardiography. 
Because of the large impedance mismatch between liquid and gas, when sound waves strike a 
microbubble, the waves are efficiently scattered back (microbubbles are excellent acoustic 
reflectors) and this is the basis for the use of microbubbles as ultrasound contrast agents. They 
are excellent reflectors of sound energy and hence are outstanding contrast agents for 
biomedical ultrasound imaging. Furthermore, the design of special ultrasound pulse 
sequences as 2nd harmonic imaging and phase inversion harmonic imaging has helped to 
increase ultrasound imaging by eliminating significant amounts of noise from tissue reflection.   
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Fig. 1. Depicts a microbubble coated with a film of stabilizing material.  
 
 
Fig. 2. Shows a contrast-enhanced echocardiogram image of a porcine heart after occlusion 
of the left anterior descending coronary artery (model of acute myocardial infarction). The 
area of decreased perfusion in the left ventricular wall is clearly seen on the post contrast 
images but was not detectable without contrast. 
When ultrasound encounters the acoustic interface of a microbubble not only may the 
ultrasound be scattered, but also, because of their size and the fortuitous insonation 
frequencies used clinically, the microbubbles also can oscillate (stable cavitation). 
Depending upon the acoustic pressure, oscillating microbubbles may rupture (cavitate – 
described further in section 4, inertial cavitation). On the basis of cavitation it was 
discovered that microbubbles had therapeutic applications for gene and drug delivery and 
treatment of vascular thrombosis. Ultrasound effects on cell membranes may be two-fold; 1) 
ultrasound itself can enhance membrane permeability, thereby allowing more diffusion 
from the extracellular milieu (sonoporation); or, 2) can be used in conjunction with 
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microbubbles to enhance localized delivery via microbubble bursting and subsequent 
radiation force induced particle penetration through the membrane surface.  Cavitation can 
be used to increase cell permeability and local delivery of materials such as DNA for gene 
therapy. 
A number of preclinical studies have been performed for gene (described further below) and 
drug delivery, but phospholipid-coated microbubbles have entered human clinical trials for 
treatment of vascular thrombosis. In these studies microbubbles have been administered 
intravenously and been shown to permeate a thrombus. Ultrasound energy has then been 
applied to the site of the clot to cavitate the microbubbles and dissolve the thrombus. 
 
 
Fig. 3. Depicts and occlusive thrombus in an arterial blood vessel (upper left). Microbubbles 
are infused IV and permeate the clot (upper right). This can be seen on ultrasound imaging. 
High energy ultrasound is focused on the site of thrombus (lower left) and the microbubbles 
cavitate, dissolving the clot and restoring blood flow. 
3. Details of microbubbles for gene delivery 
Microbubbles are mainly composed of fluorinated gases. Air and nitrogen are relatively 
water-soluble and hence will diffuse into the blood and the bubbles will then rapidly shrink 
and eventually collapse from Laplace pressures. This is not to say that air and nitrogen 
cannot be used to make microbubbles for biomedical ultrasound applications, but that 
stabilizing materials will need to be more robust to preserve the microbubbles.  
As opposed to oxygen and nitrogen being relatively soluble in water, perfluorocarbons are 
virtually insoluble in the aqueous milieu. In fact perfluorocarbons are amphiphobic. The 
higher the molecular weight of the fluorinated compound the less water soluble and we 
would predict that microbubbles prepared from that gas should be correspondingly more 
stable in the blood stream (all else equal). Note that perfluoropentane has a boiling point of 
29oC and that perfluorohexane volatilizes at 56.6oC and therefore will be a liquid at 
biological temperature (presumably due to van der Waal’s attractions). 
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Compound Molecular Weight 
Aqueous Solubility 
(Ostwald’s 
Coefficient) 
Boiling Point °C 
Nitrogen 28 18071 -196 
Oxygen 32 4865 -183 
Sulfur Hexafluoride 146 5950 -64 
Perfluoropropane 188 583 -36.7 
Perfluorobutane 238 <500 -1.7 
Perfluoropentane 288 >24 and <500 29 
Perfluorohexane 338 24 56.6 
Table 1. Potential Compounds for Making Gaseous Cores of Microbubbles 
 
 
Fig. 4. Depicts a microbubble for gene delivery. The gaseous core is coated by a monolayer 
of phospholipid containing cationic lipid imparting a net positive charge to the microbubble. 
DNA, as a polyanion, is adsorbed electrostatically to the exterior surface of the microbubble.  
With respect to the microbubble membrane, the above design demonstrates how DNA is 
adsorbed to the surface via electrostatic adhesion with cationic lipids inserted in the 
membrane. However, note also that there is no steric protection of the DNA, making it 
susceptible to biodegradation/hydrolysis. As shown below in Figure 5, microbubbles can be 
designed to incorporate PEG’ylated lipid (e.g. 8-10 mole percent PEG’ylated lipid) and we 
have still found that cationic PEG’ylated microbubbles will still adsorb useful payloads of DNA.  
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Fig. 5. Depicts a PEG’ylated cationic microbubble binding DNA. 
In vivo studies with plasmid DNA using the construct depicted in Figure 5 have shown high 
levels of gene expression in the zones of insonation. 
We predict, however, that targeted constucts that would bind to cellular targets should be 
more effective for gene delivery. Since microbubbles are micron-sized structures, they are 
not expected to extravasate from the intravscular space. However, for the purposes of 
delivering genes to regions in close proximity to targeted tissues, they can be targeted to 
eptitopes expressed on endothelial cells. Because they can also be engulfed by phagocytic 
cells, such as immune cells, and targeted as intracellular passengers, the nanoparticles fused 
to microbubble surfaces as described below  (Figure 8) can also be decorated with cell 
surface identifiers/targets, uptake enhancers, and even intracellular targets in order to 
provide additional selectivity. We have prepared targeted microbubbles to a variety of 
different targets. Depicted below is the design for a targeted microbubble to the integrin 
αvβIII, Expressed on the endothelial surface in angiogenesis. 
The microbubble construct depicted above combines several features of nanotechnology. 
The parent microbubble is PEG’ylated to impart stealth properties in order to prevent 
reticuloendothelial system elimination and includes targeting ligands directed to epitopes 
expressed on endothelial cells. It could be monitored as an ultrasound contrast agent and 
then activated with higher energy ultrasound using low MI ultrasound for imaging to 
monitor delivery to the target site and high MI ultrasound energy for cavitation. Upon 
activation the nanoparticles containing DNA would be expected to extravasate from the 
vasculature into the interstitial tissues. The nanoparticles could be constructed to contain 
targeting ligands and/or cell penetration-enhancing agents to facilitate uptake by target 
cells. A challenge is to design linkers to attach the nanoparticles to the surface of the parent 
microbubbles. One approach would be to biotinylate the nanoparticles and to have avidin 
tethers attached to the parent microbubbles taking advantage of the avidin/biotin 
interaction. This approach could be utilized in proof-of-principle studies but would not be  
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Fig. 6. Depicts a targeted microbubble. The cyclo-CRGDC analog is attached to a lipid 
anchor via a PEG spacer to form a bioconjugate. The bioconjugate comprises about from 
about 0.1 to 5 mole percent of the lipid coating the microbubble. There is additional 
PEG’ylated lipid from about 5-10 mole percent in the lipid coating the microbubble. 
 
 
Fig. 7. Depicts a targeted cationic microbubble binding DNA. The bioconjugates are 
designed to bind to endothelial epitopes upregulated in disease. The microbubble can be 
followed and monitored by ultrasound imaging and activated with ultrasound energy for 
local delivery. 
Targeted Microbubbles - Design 
• Anchor: lipid  
• Tether: PEG 
• Ligand: pep de 
Anchor Tether 
Ligand 
CRGDWPC 
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clinically translatable. A maleimide labeled spacer might be affixed to the microbubble and 
the nanoparticles might be thiolated to covalently bind the nanoparticle to the surface of the 
microbubbles in a potentially biocompatible manner. Another approach would be to use 
electrostatic interaction between the nanoparticle and the surface of the microbubbles but 
this must be optimized to ensure that the DNA is bound until it reaches the target site. Note 
also that if the bubble has excess cationic charge this may adversely affect biodistribution. 
Note also that it is more difficult to bind low molecular weight genetic material such as si-
RNA using merely electrostatic interaction. 
 
 
Fig. 8. Depicts a unique microbubble construct for gene delivery. The parent microbubble is 
PEG’ylated but the DNA (or siRNA) is condensed into nanoparticles that are bound to the 
surface of the microbubble. The nanoparticles have targeting ligands to bind to cell specific 
epitopes. Note also that the construct could be modified to comprise endothelial targeting 
moieties on the microbubble so that the microbubble could bind to endothelial epitopes. 
4. Ultrasound – parameters and bioeffects 
Ultrasound is a commonly used modality for biomedical imaging, only exceeded by X-
rays in overall worldwide use. For medical imaging the power or intensity of ultrasound 
that can be used is limited by regulatory guidelines. The intensity of the ultrasound can be 
described by the mechanical index (MI) which is related to the peak negative pressure of 
the ultrasound wave divided by the square root of the center frequency of the ultrasound. 
The FDA-approved mechanical index for most body imaging ultrasound (e.g. cardiac and 
abdominal) is limited to an MI < 1.9. For neurovascular imaging it is limited to MI < 1.0 
and for ophthalmic ultrasound to MI < 0.8.  
Cavitation is a phenomenon in which ultrasound exposure at the resonance frequency of 
the microbubble will induce expansion and collapse of microbubbles (Apfel, Hallow). 
This can occur spontaneously at high acoustic pressure in the absence of exogenous 
microbubbles. Sufficiently high acoustic power is sufficient to create a microbubble nidus 
in situ and cause expansion and collapse, i.e. cavitation (Marmottant). Cavitation causes 
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acoustic streaming and local shock waves that may radiate on the order of microns or 
larger depending upon the acoustic intensity and other factors (Mehier-Humbert). 
Cavitation can be used to increase cell permeability (i.e. sonoporation)(Deng), open the 
blood brain barrier or destroy tissues (i.e. sonoablation)(Conger, Feril). The acoustic 
pressure can be controlled to create the desired effects (Forsberg). Within the ranges of 
allowable acoustic pressures, in the absence of exogenous microbubbles, biomedical 
ultrasound imaging does not generally cause violent cavitation and ultrasound imaging is 
generally quite safe, particularly compared to other technologies such as X-ray imaging 
that uses ionizing radiation.  
As shown below in Figure 9, microbubbles lower the threshold of ultrasound energy 
necessary for cavitation to occur. The effect is frequency dependent with a greater 
proportional effect at 1 MHz than at 10 MHz. Note that at 1 MHz, cavitation occurs at MI < 
0.5 within the allowable ultrasound power limits for biomedical imaging. Note that 
microbubbles in the size range of 0.5 to 2.0 microns are quite effective in lowering the 
thresh-hold of energy for cavitation. Stable microbubbles for gene delivery can certainly be 
made in this size range. If necessary, for therapeutic applications, higher levels of 
ultrasound energy can be employed. Higher levels of ultrasound energy are used 
therapeutically for hyperthermia and focused ultrasound surgery (Brujan). 
 
 
Fig. 9. Microbubbles Lower Thresh-hold of Ultrasound Energy for Cavitation (Apfel). 
Figure 10, below, shows images from ultra-high speed videomicroscopy of a single bubble in 
response to a single high MI pulse of ultrasound energy. The microbubble expands, collapses, 
and fragments. The daughter fragments then undergo one additional cycle of expansion, 
collapse and disappear. In this process genetic materials might be released from a gene-
carrying microbubble. The cavitation process will also create acoustic jets and streaming which 
might be used for delivering the genetic material to the target tissue or cells. 
Figure 11 depicts a gene carrying microbubble in response to cavitation. The stabilizing wall 
material of the microbubble fragments and the genetic material is ejected with the cavitation 
ballistically, thereby extravasating from the vasculature to the target tissue. 
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Fig. 10. Videomicroscopy images of a single bubble in response to a single ultrasonic wave. 
 
 
Fig. 11. A drug carrying-microbubble cavitating in response to ultrasound. 
Another major mechanism in ultrasound that may be useful for drug and gene delivery is 
the mechanical force of microbubbles. Ultrasound exerts a radiation (pushing) force that can 
move microparticles and improve cellular delivery of biomaterials. Figure 12 below shows 
avidin-coated microbubbles flowing in blood over a biotinylated plate. The microbubbles 
flow and do not appear to bind but after application of relatively low MI ultrasound the 
microbubbles are pushed by the acoustic waves and bind to the surface of the plate. The 
same process can be used to improve cellular uptake of biomaterials such as DNA. The 
(pushing) radiation force of ultrasound occurs at lower energies than necessary for 
cavitation and can be used to increase efficacy from gene delivery. 
An acoustic transducer that generally uses a piezoelectric material to convert electrical energy 
into ultrasound waves creates ultrasound waves. The transducer design varies depending 
upon the biomedical application. Figure 13 (below) shows the design of a three dimensional 
transducer for imaging and treating the heart. This transducer can be used to image the heart 
and visualize microbubble as they enter the myocardial circulation. Ultrasound energy can be 
applied to the heart to cavitate the microbubbles or for the radiation force to improve 
myocardial delivery. The transducer is currently being used in pre-clinical studies for 
microbubble enhanced sonothrombolysis to treat myocardial infarction and planned for use in 
clinical studies. The same transducer design could potentially be used in clinical studies for 
microbubble-mediated gene delivery to treat the heart. 
Despite its ease of use, unwanted bioeffects can be experienced using ultrasound at high 
acoustic outputs.  High levels of ultrasound energy with cavitation may cause cell damage, 
cell death and apoptosis (Miller). Ultrasound may also heat tissues and cause coagulative 
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necrosis at high temperatures (Ter Haar). We emphasize, however, that ultrasound power 
levels within the limits for diagnostic ultrasound are generally safe. Ultrasound power 
levels can be optimized for gene therapy to maximize gene expression while minimizing 
unwanted bioeffects (Chen, Rahim). 
 
 
Fig. 12. Drawing of three-dimensional transducer for imaging and treating the heart. 
5. Studies using microbubbles and ultrasound for gene delivery 
In this section we summarize studies that have been performed using microbubbles and 
ultrasound for gene delivery (Klibanov, Liu, Newman). 
Over the period of more that a decade a number of different studies have been performed, in 
vitro and in vivo. In vitro studies showed that ultrasound increased the efficacy of transfection 
with cationic liposomes in cell culture studies to express reporter genes. Saphenous vein grafts 
have been transfected with ultrasound and MBs (Kodama) to enhance graft survival after 
implantation (Akowuah). In vivo studies have been performed with reporter genes showing 
increased expression of the reporter gene after IV administration of microbubbles either 
binding or in association with the reporter genes. The zones of highest expression have been in 
the regions of tissues of insonation (except that cationic microbubbles have also been 
accumulated by liver, lungs, spleen and phagocytic organs). Most of the in vivo studies Have 
been performed with reporter genes. A few studies have performed with therapeutic genes. A 
wide variety of different tissues (Hauff) and cells have shown enhanced transfection with 
ultrasound including neuronal cells (Fischer) and skeletal muscle (Liang). 
A number of groups have studied ultrasound and microbubbles to transfect tumors (Michel, 
Anwer). With collaborators we performed a study assessing tumor regression with 
transfection of the IL-12 gene with ultrasound and cationic liposomes (Anwer). In this study 
the liposomes were lyophilized and may have contained nitrogen gas. The tumors were 
insonated with 1 MHz ultrasound. Increased expression of IL-2 was observed in the 
insonated tumors and statistically significant tumor regression. 
In addition to phospholipid coated microbubbles, MBs can be stabilizes with denatured serum 
albumin (e.g. Optison®, GE Healthcare Medical Diagnostics, Princeton, NJ). Albumin binds a 
variety of molecules and also appears to bind DNA. In one study the plasmid of AdCMV-b-
Gal was attached to the microbubbles (Shohet). In these studies the solution of AdCMV-b-Gal 
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was added to the microbubble suspension and mixed for 2 hours at 4°C. The mixture was 
separated into 2 distinct layers. The upper layer consisted of microbubbles with attached virus; 
the bottom layer, which contained unattached virus, was discarded. The concentration of 
microbubbles with attached AdCMV-β-Gal was 1.2x109 bubbles/mL; the mean diameter was 
3.5 um. The viral titer of these microbubbles was determined. Rats were anesthetized, and MBs 
were administered IV. Echocardiography was performed at 1.3 MHz with a mechanical index 
of 1.5. Images were ECG-triggered to deliver a burst of 3 frames of ultrasound every 4 to 6 
cardiac cycles. The hearts of all 6 rats in the experimental group showed blue staining with 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside. None of the control rats showed myocardial 
staining, which confirmed that the destruction of the microbubbles containing the virus was 
responsible for the observed β-galactosidase expression in the rat myocardium. 
Initiated in 2001, researchers began using gas-filled, albumin-shelled MBs (Optison) and 
non-viral carriers to increase nascent serum HDL cholesterol in mice and Sprague-Dawley 
rats.  Initial feasibility studies were performed using reporter genes, 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside and GFP.  Subsequent studies now use ApoA-I DNA 
plasmids in combination with Optison.  In a series of rat studies performed with partial 
support from an NIH SBIR award (44HL095238-01), the results revealed that an average 
peak response of HDL-C elevation occurred within 24 hours of treatment and 88% of the 
responses occurred within 48 hours.  The control animal group included ultrasound only, 
apoA-I DNA only, and microbubble only rats. These data demonstrated a rapid 
incorporation of the plasmid into the cell and efficient ApoA-I protein production that was 
later incorporated into serum HDL-C.  
Summarized data revealed an average increase of 16.8% on day one post treatment. Due to 
wide normal variation in individual rat HDL cholesterol values, all data is plotted as a 
percentage from an individual animal’s baseline.  When examining the overall response to 
treatment in mg/dL, the average peak response to treatment was 14.0% (p-value <0.0001) as 
seen in Figure 1 (below).  This response was observed uniformly across different animals 
and ranged from 40mg/dL HDL-C baseline to 100mg/dL HDL-C baseline.   
Ongoing studies include additional design of experiments for the following: (1) 
optimization of sonoporation utility for raising HDL cholesterol, (2) efficient energy delivery 
algorithms, (3) modes and methods of delivery, and (4)  mechanistic analyses of the intra-
cellular plasmid location.  
Ongoing studies have been performed with lipid coated MBs binding plasmid DNA with 
genes to treat diabetes. In vivo studies in rats have shown long-term normalization of blood 
glucose levels in diabetic rats. Studies are planned to test this system in primates. 
Encouraging work has been performed in models of hypercholesterolemia showing the 
potential to perform gene therapy for H1Alpha to improve the capacity of the liver to produce 
HDL as treatment for atherosclerosis. Promising work continues to progress in the use of MBs 
binding genes to treat hemophilia. Cationic MBs binding DNA (similar to Figure 7) have been 
tested with ultrasound and compared to DefinityR MBs which do not bind DNA. Expression 
of Factor IX transgenes is more robust with the cationic MBs binding DNA than with MBs not 
binding DNA. In both the HI1Alpha/HDL and hemophilia treatment applications the target 
organ is the liver. The goal in both of these programs and in many others is to generate 
sustained transgene expression in the liver (Guo). Catheter mediated administration may 
prove attractive to maximize efficiency of delivery to hepatocytes and catheters can be 
deployed for delivery to other organs such as the kidneys, heart and blood vessels. 
Ultrasound can be targeted to any organ for which it is possible to create an acoustic 
window. Most tissues are readily accessible to ultrasound. Ultrasound can be applied across  
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Fig. 13. Baseline to peak response measurement in 30 treated rats recorded in raw data 
values of mg/dL. A statically significant 14% increase was measured (p-value= 0.0001). 
the intact skin or, if need be, via specialized probes. While ultrasound is blocked by 
air/tissue or air/fluid interfaces, even in the lung, it is possible to create acoustic windows 
to the bronchi with bronchoscopes and water filled balloons. Ultrasound can be targeted 
precisely to tissues to treat volumes of tissues ranging to more than 500 ml to less than a ml. 
Most studies have shown relatively low toxicity due to ultrasound and MBs. It also is 
possible to repeat treatment, potentially indefinitely.  
Despite early studies in ultrasound and gene delivery with MBs being performed more 
than a decade ago, none of the ultrasound gene delivery programs with MBs, at the 
time of preparation of this chapter, have advanced to clinical trials. The field is still early 
in its development, but the tolerability, ease of use and high degrees of expression in the 
target tissue indicate that this technology merits serious consideration for clinical 
translation. 
6. Conclusions 
Ultrasound mediated gene delivery with acoustically active carriers (e.g. microbubbles) is a 
promising field that affords the potential for high levels of expression in the target tissue 
without the adverse bioeffects of viral-based carriers. The field is early in its development 
however as no clinical studies have yet been performed as of the time of preparation of this 
manuscript. Clinical development of this promising field will require identification of 
biological targets in areas of medical need and multi-disciplinary collaborations between 
material scientists, biologists and biopharma. 
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